Company intelligence / Profile preview

GoLiver Therapeutics

Nantes, Pays de la Loire, Francegolivertx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Developing injectable hepatocytes produced from human pluripotent stem cells to treat liver diseases as an alternative to liver transplantation. Recently awarded €1.6 million from France 2030 to progress their first biomedicine into clinical trials.

Therapeutic areas: Gastroenterology
Modalities: Cell therapyAdvanced Therapy Medicinal Products (ATMP)
Industry: Biotech

Drug pipeline

1 asset

GLTX-001

Preclinical

Beyond the preview

Go deeper on GoLiver Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GoLiver Therapeutics.

Explore the full profile